×

Stocks Pfizer Inc

  • What follows is a roundup of corporate earnings reports for Tuesday, May 4.

  • This trend is driving the markets right now.

  • With the Dow plunging more than 200 points on Tuesday, is this the start of the market correction that bears have been calling for? Alan Valdes, vice president of Kabrick Trading, and Warren Meyers, CEO of Walter J. Dowd, offered CNBC their global market outlooks.

  • Debtor Nations

    The Dow plunged more than 200 points Tuesday as the dollar rallied against the euro amid worries about the European debt crisis.

  • With the euro at 1-year lows, these may be the companies that could feel the most pain next earnings season.

  • Debtor Nations

    U.S. futures, which were weak overnight on weakness in Europe and China, dropped a few more points near 8am ET on word that an improvised explosive device (IED) was found in a vehicle outside Aldgate East in London—a false alarm, according to reports. Greece and Spain are down about 4 percent, the rest of Europe down 1 to 2 percent. Why don't equity traders believe the Greek bailout will be helpful?

  • U.S. stocks fell sharply Tuesday, with the Dow down more than 200 points, as the dollar rallied against the euro amid worries about the European debt crisis.

  • Considering shares of Pfizer are down about 7% year to date, how should you game this stock in the wake of earnings, Tuesday?

  • NYSE Traders

    The question for markets in the week ahead will be whether to ride a wave of better economic and earnings news—or give in to a growing list of worries.

  • Cramer thinks next week's jobs report will show more people are getting hired and the DOW will rise. So how will individual stocks fare? Here's his day-by-day breakdown.

  • What do Greenlight Capital, Blue Ride Capital and T2 Advisors all have in common? They’re all bullish this name.

  • Markets rose on Friday after fluctuating in a tight range throughout the session after a weak open on Friday. How should investors be positioned going forward? Peter Costa, president of Empire Executions and CNBC market analyst and Richard Regan, founder and managing partner at Protradingcourse.com shared their insights.

  • Earnings season kicked off with a thud on Monday as Alcoa missed on revenue for the first time since 2007. However, analysts expect earnings to be decent overall. Tom Lydon, editor of ETF Trends and David Dietze, president and chief investment strategist at Point View Financial Services shared their insights.

  • Crude oil will hit $100 a barrel while gold will reach $1,500 an ounce by the end of this year, said Byron Wien, vice chairman of Blackstone Advisory Services.

  • Stocks slipped Wednesday after a senior Fed member said policy makers should start raising rates to 1 percent soon.

  • Stocks slipped Wednesday after a senior Fed member said policy makers should start raising rates to 1 percent soon.

  • greenspan_140.jpg

    Former chairman of the Federal Reserve Alan Greenspan reinforced increasingly confident assessments by the Obama administration that the nation’s latest job numbers reveal a resurgent economy.

  • Jeff Kindler, Pfizer Chairman and CEO

    The world’s largest drug company, Pfizer, has handled mergers badly, invented too few drugs and left its reputation in disrepair after two criminal cases.  And that is the assessment of its own chief executive. The NYT talks to Pfizer CEO Jeffrey Kindler.

  • Now that the markets closed 4% or higher for the quarter, a positive first quarter is a good indication for the year where historically the Dow, S&P and NASDAQ Composite have managed to post average gains of more than 12% in the year when Q1 was a positive quarter versus average losses of -0.2% or greater when Q1 was negative.

  • Stocks pulled off a gain Tuesday after a see-saw session as techs and industrials gained, while energy and bank stocks were weak.